IOVA:NSD-Iovance Biotherapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 11.47

Change

0.00 (0.00)%

Market Cap

USD 1.80B

Volume

4.14M

Avg Analyst Target

USD 25.47 (+122.03%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

IOVA Stock Forecast & Price:
Based on the Iovance Biotherapeutics Inc stock forecasts from 10 analysts, the average analyst target price for Iovance Biotherapeutics Inc is USD 25.47 over the next 12 months. Iovance Biotherapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Iovance Biotherapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Iovance Biotherapeutics Inc’s stock price was USD 11.47. Iovance Biotherapeutics Inc’s stock price has changed by +3.05% over the past week, +46.11% over the past month and -56.65% over the last year.

About Iovance Biotherapeutics Inc (IOVA:NSD)

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144 ...Read More

Company Website : https://www.iovance.com

Address : 825 Industrial Road, San Carlos, CA, United States, 94070

Employees : 319

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.91

52 Week High : 27.96

Short Ratio : 2.24

52 Week Low : 6.18

Shorted Shares : 16,555,432

200 Day Moving Average : 17.32

Shorted Shares Previous Month : 17,372,830

50 Day Moving Average : 11.99

Shares Held By Insiders : 0.47%

Short Percentage : 11.07%

Shares Held by Institutions : 104.39%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

N/A

 USD73.48B 29.71 20.69
REGN Regeneron Pharmaceuticals Inc

N/A

 USD65.40B 8.39 6.52
MRNA Moderna Inc

N/A

 USD59.64B 4.20 2.94
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

 USD38.28B 2.86 1.54
SGEN Seagen Inc

N/A

 USD33.15B 55.02 -50.53
RPRX Royalty Pharma Plc

N/A

 USD28.81B 29.89 16.26
GMAB Genmab AS

N/A

 USD21.88B 64.29 5.76
ARGX argenx NV ADR

N/A

 USD20.61B N/A -30.89
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing IOVA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -39.92% 56% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.92% 56% F 34% F
Trailing 12 Months  
Capital Gain -56.65% 61% D- 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.65% 61% D- 32% F
Trailing 5 Years  
Capital Gain 57.12% 78% C+ 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.12% 78% C+ 73% C
Average Annual (5 Year Horizon)  
Capital Gain 38.54% 78% C+ 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.54% 78% C+ 86% B
Risk Return Profile  
Volatility (Standard Deviation) 81.28% 32% F 17% F
Risk Adjusted Return 47.41% 86% B 78% C+
Market Capitalization 1.80B 90% A- 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.17 32% F 27% F
Price / Cash Flow Ratio -7.91 77% C+ 76% C
EV/EBITDA -3.93 79% C+ 77% C+
Management Effectiveness  
Return on Equity -59.76% 48% F 20% F
Return on Invested Capital -53.58% 51% F 19% F
Return on Assets -30.90% 38% F 12% F
Debt to Equity Ratio 0.16% 89% B+ 90% A-
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.24 74% C 62% D-
Short Percent 11.07% 20% F 16% F
Beta 0.91 73% C 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector